Suppr超能文献

PD-1 可防止 T 细胞介导的心肌炎中的炎症和心肌细胞损伤。

PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.

机构信息

Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

出版信息

J Immunol. 2012 May 15;188(10):4876-84. doi: 10.4049/jimmunol.1200389. Epub 2012 Apr 9.

Abstract

PD-1, a member of the CD28 family of immune regulatory molecules, is expressed on activated T cells, interacts with its ligands, PD-L1/B7-H1 and PD-L2/B7-DC, on other cells, and delivers inhibitory signals to the T cell. We studied the role of this pathway in modulating autoreactive T cell responses in two models of myocarditis. In a CD8(+) T cell-mediated adoptive transfer model, we found that compared with Pd1(+/+) CD8(+) T cells, Pd1(-/-) CD8(+) T cells cause enhanced disease, with increased inflammatory infiltrate, particularly rich in neutrophils. Additionally, we show enhanced proliferation in vivo and enhanced cytotoxic activity of PD-1-deficient T lymphocytes against myocardial endothelial cells in vitro. In experimental autoimmune myocarditis, a disease model dependent on CD4(+) T cells, we show that mice lacking PD-1 develop enhanced disease compared with wild-type mice. PD-1-deficient mice displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased infiltration of inflammatory cells, including CD8(+) T cells. Together, these studies show that PD-1 plays an important role in limiting T cell responses in the heart.

摘要

PD-1 是 CD28 家族免疫调节分子的成员,表达于活化的 T 细胞上,与其他细胞上的配体 PD-L1/B7-H1 和 PD-L2/B7-DC 相互作用,并向 T 细胞传递抑制信号。我们在两种心肌炎模型中研究了该途径在调节自身反应性 T 细胞反应中的作用。在 CD8(+)T 细胞介导的过继转移模型中,我们发现与 Pd1(+/+)CD8(+)T 细胞相比,Pd1(-/-)CD8(+)T 细胞导致疾病加重,炎症浸润增加,特别是富含中性粒细胞。此外,我们还显示体内 PD-1 缺陷 T 淋巴细胞增殖增强,体外对心肌内皮细胞的细胞毒性活性增强。在依赖 CD4(+)T 细胞的实验性自身免疫性心肌炎疾病模型中,我们发现与野生型小鼠相比,缺乏 PD-1 的小鼠疾病加重。PD-1 缺陷小鼠显示出炎症增加、心肌损伤的血清标志物增加以及炎症细胞浸润增加,包括 CD8(+)T 细胞。综上所述,这些研究表明 PD-1 在限制心脏中的 T 细胞反应中发挥重要作用。

相似文献

1
PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.
J Immunol. 2012 May 15;188(10):4876-84. doi: 10.4049/jimmunol.1200389. Epub 2012 Apr 9.
2
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7. doi: 10.1161/ATVBAHA.111.224709. Epub 2011 Mar 10.
3
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
Circulation. 2007 Oct 30;116(18):2062-71. doi: 10.1161/CIRCULATIONAHA.107.709360. Epub 2007 Oct 15.
4
Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.
Int J Mol Sci. 2021 Jan 31;22(3):1426. doi: 10.3390/ijms22031426.
7
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.
J Exp Med. 2012 Dec 17;209(13):2485-99. doi: 10.1084/jem.20121015. Epub 2012 Dec 10.
8
B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
J Immunol. 2012 Sep 1;189(5):2338-47. doi: 10.4049/jimmunol.1103085. Epub 2012 Jul 25.
10
Abrogation of functional selectin-ligand expression reduces migration of pathogenic CD8+ T cells into heart.
J Immunol. 2006 Jun 1;176(11):6568-75. doi: 10.4049/jimmunol.176.11.6568.

引用本文的文献

1
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis.
Invest New Drugs. 2025 Aug 13. doi: 10.1007/s10637-025-01575-y.
2
Cancer Therapy-Related Cardiac Dysfunction in Patients Using Immune Checkpoint Inhibitors: A Multicenter Study.
JACC Asia. 2025 Jul;5(7):942-945. doi: 10.1016/j.jacasi.2025.04.009. Epub 2025 Jun 17.
3
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers.
Hum Vaccin Immunother. 2025 Dec;21(1):2512645. doi: 10.1080/21645515.2025.2512645. Epub 2025 Jun 12.
4
The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.
Front Immunol. 2025 May 26;16:1605958. doi: 10.3389/fimmu.2025.1605958. eCollection 2025.
6
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.
Nat Cardiovasc Res. 2025 May;4(5):526-538. doi: 10.1038/s44161-025-00640-2. Epub 2025 May 7.
7
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.
Front Immunol. 2025 Apr 4;16:1561968. doi: 10.3389/fimmu.2025.1561968. eCollection 2025.
8
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.
JACC CardioOncol. 2025 Apr;7(3):234-248. doi: 10.1016/j.jaccao.2025.01.020.
9
Deep insight into cytokine storm: from pathogenesis to treatment.
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.

本文引用的文献

1
Cancer immunotherapy comes of age.
J Clin Oncol. 2011 Dec 20;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899. Epub 2011 Oct 31.
2
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7. doi: 10.1161/ATVBAHA.111.224709. Epub 2011 Mar 10.
4
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
J Exp Med. 2010 Sep 27;207(10):2187-94. doi: 10.1084/jem.20100643. Epub 2010 Sep 6.
5
The PD-1 pathway in tolerance and autoimmunity.
Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x.
6
Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation.
J Immunol. 2010 Aug 1;185(3):1375-8. doi: 10.4049/jimmunol.0903369. Epub 2010 Jul 2.
8
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells.
Nat Immunol. 2010 Jun;11(6):535-42. doi: 10.1038/ni.1877. Epub 2010 May 9.
9
PD-1 deficiency results in the development of fatal myocarditis in MRL mice.
Int Immunol. 2010 Jun;22(6):443-52. doi: 10.1093/intimm/dxq026. Epub 2010 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验